JP4988551B2 - ２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物 - Google Patents

２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物 Download PDF

Info

Publication number
JP4988551B2
JP4988551B2 JP2007507308A JP2007507308A JP4988551B2 JP 4988551 B2 JP4988551 B2 JP 4988551B2 JP 2007507308 A JP2007507308 A JP 2007507308A JP 2007507308 A JP2007507308 A JP 2007507308A JP 4988551 B2 JP4988551 B2 JP 4988551B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
group
methylene
dinor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007507308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007532540A5 (enExample
JP2007532540A (ja
Inventor
デルーカ，ヘクター・エフ
バーリッキー，ラファル
グルズィワクズ，パウェル・ケイ
プラム，ロリ・エイ
シシンスキ，ラファル・アール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of JP2007532540A publication Critical patent/JP2007532540A/ja
Publication of JP2007532540A5 publication Critical patent/JP2007532540A5/ja
Application granted granted Critical
Publication of JP4988551B2 publication Critical patent/JP4988551B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2007507308A 2004-04-09 2005-02-04 ２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物 Expired - Fee Related JP4988551B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/821,828 US7713951B2 (en) 2004-04-09 2004-04-09 2-alkylidene-18,19-dinor-vitamin D compounds
US10/821,828 2004-04-09
PCT/US2005/003378 WO2005102995A1 (en) 2004-04-09 2005-02-04 2-alkylidene-18,19-dinor-vitamin d compounds

Publications (3)

Publication Number Publication Date
JP2007532540A JP2007532540A (ja) 2007-11-15
JP2007532540A5 JP2007532540A5 (enExample) 2008-03-21
JP4988551B2 true JP4988551B2 (ja) 2012-08-01

Family

ID=34960524

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007507308A Expired - Fee Related JP4988551B2 (ja) 2004-04-09 2005-02-04 ２−アルキリデン１８，１９−ジノル−ビタミンｄ化合物

Country Status (9)

Country Link
US (2) US7713951B2 (enExample)
EP (1) EP1735277B1 (enExample)
JP (1) JP4988551B2 (enExample)
AT (1) ATE534623T1 (enExample)
AU (1) AU2005235957B2 (enExample)
CA (1) CA2562535C (enExample)
MX (1) MXPA06011499A (enExample)
NZ (1) NZ550234A (enExample)
WO (1) WO2005102995A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834050B2 (en) 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones
JP2009532457A (ja) * 2006-04-06 2009-09-10 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α−ヒドロキシ−１８，１９，２１−トリノルビタミンＤ３類縁体およびその使用
US7704981B2 (en) * 2006-04-06 2010-04-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof
US20110274743A1 (en) * 2009-01-16 2011-11-10 Pharmaceutical Compounding Nz Limited Medicament for the Treatment of Pain and Inflammation
CA2777938C (en) * 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
JP5931845B2 (ja) * 2010-03-23 2016-06-08 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
CA2794006C (en) * 2010-03-23 2017-11-28 Wisconsin Alumni Research Foundation (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3
JP5930467B2 (ja) * 2012-12-14 2016-06-08 花王株式会社 ニトリル化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67153A (en) 1981-11-02 1986-12-31 Res Inst Medicine Chem Intermediates in the production of vitamin d analogues and method for their production
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
EP0474517B1 (en) 1990-09-07 1998-11-18 Wisconsin Alumni Research Foundation Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
JP4235256B2 (ja) * 1993-07-09 2009-03-11 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント 新規ビタミンｄ構造類似体
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
BR9509739A (pt) 1994-11-21 1997-10-21 Wisconsin Alumni Res Found Compostos 18,19-dinor-vitamina d
US5661140A (en) * 1994-11-21 1997-08-26 Wisconsin Alumni Research Foundation 18-nor-vitamin D compounds
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
IL118156A (en) 1995-05-09 2001-08-26 Duphar Int Res Vitamin d compounds, their preparation and pharmaceutical compositions containing them
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
TW396427B (en) * 1998-12-16 2000-07-01 United Microelectronics Corp Method for fabricating double gates in semiconductor
WO2001092221A1 (en) * 2000-05-31 2001-12-06 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
CA2416194C (en) * 2000-07-14 2009-10-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
ATE273709T1 (de) * 2000-09-08 2004-09-15 Wisconsin Alumni Res Found 1alpha-hydroxy-2-methylene-19-nor- homopregnacalciferol und seine therapeutische verwendungen
BR0307896A (pt) * 2002-03-29 2004-12-07 Wisconsin Alumni Res Found Método de produção de 1(alfa)-hidroxi-2-metileno-19-nor-homopregnacalcif erol
EP1559708A4 (en) * 2002-10-10 2006-07-19 Wisconsin Alumni Res Found 2,2-DISUBSTITUTED 1A, 25-DIHYDROXY-19-NORVITAMINE D DERIVATIVE
JP5005340B2 (ja) * 2003-04-10 2012-08-22 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ２−プロピリデン−１９−ノル−ビタミンｄ化合物
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
AU2004266706B2 (en) * 2003-08-20 2009-07-30 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D2 compounds
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
MXPA06005887A (es) * 2003-11-25 2006-06-27 Wisconsin Alumni Res Found Analogos de vitamina d para la prevencion y el tratamiento de la obesidad.
US7053075B2 (en) * 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
EP1817278B1 (en) * 2004-11-22 2010-06-30 Wisconsin Alumni Research Foundation 2-methylene-18,19-dinor-1alfa-hydroxy-homopregnacalciferol and its uses
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
DK1848442T3 (da) * 2005-02-11 2012-05-29 Wisconsin Alumni Res Found 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2
US7241909B2 (en) * 2005-05-03 2007-07-10 Wisconsin Alumni Research Foundation 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds

Also Published As

Publication number Publication date
CA2562535A1 (en) 2005-11-03
EP1735277A1 (en) 2006-12-27
AU2005235957B2 (en) 2011-08-04
WO2005102995A1 (en) 2005-11-03
CA2562535C (en) 2012-07-10
ATE534623T1 (de) 2011-12-15
US7713951B2 (en) 2010-05-11
US20100179344A1 (en) 2010-07-15
EP1735277B1 (en) 2011-11-23
MXPA06011499A (es) 2007-01-16
JP2007532540A (ja) 2007-11-15
US20050227950A1 (en) 2005-10-13
AU2005235957A1 (en) 2005-11-03
NZ550234A (en) 2010-07-30

Similar Documents

Publication Publication Date Title
KR100345820B1 (ko) 2-알킬-19-노르-비타민 ｄ 화합물
EP1268415B1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
US7531527B2 (en) 2-Propylidene-19-nor-vitamin D compounds
AU2001247873A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds
US20100179344A1 (en) 2-Alkylidene-18,19-Dinor-Vitamin D Compounds
JP5009617B2 (ja) ２−メチレン−１９−ノル−ビタミンｄ２化合物
JP5043673B2 (ja) １７，２０（ｅ）−デヒドロビタミンｄ類似体およびそれらの使用
EP2714656B1 (en) (22e)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin d3 derivatives
JP2013506685A (ja) （２０Ｓ，２２Ｅ）−２−メチレン−１９−ノル−２２−エン−１α，２５−ジヒドロキシビタミンＤ３類似体
JP5043674B2 (ja) ２−メチレン−１８，１９−ジノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用
US7235680B2 (en) 2-methylene-19-nor-(23S)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1α-hydroxyvitamin D3-26,23-lactone

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110823

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110830

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120329

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120426

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150511

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees